CTKB logo

Cytek Biosciences, Inc. Stock Price

NasdaqGS:CTKB Community·US$534.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

CTKB Share Price Performance

US$4.00
-0.14 (-3.38%)
US$6.00
Fair Value
US$4.00
-0.14 (-3.38%)
33.3% undervalued intrinsic discount
US$6.00
Fair Value
Price US$4.00
AnalystConsensusTarget US$6.00
AnalystLowTarget US$5.00
AnalystHighTarget US$7.50

CTKB Community Narratives

AnalystConsensusTarget·
Fair Value US$6 33.3% undervalued intrinsic discount

Cloud Software And Flow Cytometry Will Unlock Global Opportunity

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·
Fair Value US$5 20.0% undervalued intrinsic discount

Rising Costs And Trade Tensions Will Shrink Flow Cytometry Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$7.5 46.7% undervalued intrinsic discount

Growing Global Healthcare Investment And AI Will Advance Cytometry Adoption

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

Updated Narratives

CTKB logo

CTKB: Sector Recovery And 2026 Guidance Are Expected To Drive Upside

Fair Value: US$6 33.3% undervalued intrinsic discount
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CTKB logo

CTKB: 2026 Guidance And Multi Year Framework Will Support Upside Potential

Fair Value: US$5 20.0% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CTKB logo

CTKB: Sector Recovery And 2026 Earnings Framework Will Drive Repricing

Fair Value: US$7.5 46.7% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

1 Risk
0 Rewards

Cytek Biosciences, Inc. Key Details

US$201.5m

Revenue

US$97.0m

Cost of Revenue

US$104.5m

Gross Profit

US$171.0m

Other Expenses

-US$66.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.52
51.84%
-33.02%
2.0%
View Full Analysis

About CTKB

Founded
1992
Employees
702
CEO
Wenbin Jiang
WebsiteView website
cytekbio.com

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Recent CTKB News & Updates

Recent updates

No updates